The DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Activation of PI3K‐Akt signaling pathway promotes prostate cancer cell invasion
Abstract
Activated phosphoinositide 3‐kinase (PI3K) and its downstream target Akt/PKB are important signaling molecules and key survival factors involved in the control of cell proliferation, apoptosis and oncogenesis. We investigated the role of the PI3K‐Akt signaling pathway in the invasion of prostate cancer cell lines and activation of this pathway in primary human prostate tumors. Treatment of human prostate cancer cells viz. LNCaP, PC‐3 and DU145 with PI3K pharmacological inhibitor, LY294002, potentially suppressed the invasive properties in each of these cell lines. Restoration of the PTEN gene to highly invasive prostate cancer PC‐3 cells or expression of a dominant negative version of the PI3K target, Akt also significantly inhibited invasion and downregulated protein expression of urokinase‐type plasminogen activator (uPA) and matrix metalloproteinase (MMP)‐9, markers for cell invasion, indicating a central role of the PI3K‐Akt pathway in this process. Immunoblot analysis of PI3K and total/activated levels of Akt showed increased protein levels of catalytic (p110α/β) and regulatory (p85) subunits of PI3K and constitutive Akt activation in high‐grade tumors compared to low‐grade tumor and benign tissue. Immunohistochemical analyses further confirmed a progressive increase in p‐Akt (p‐Ser473) levels but not of total‐Akt (Akt1/2) in cancer tissues compared to benign specimens. A successive increase in p‐Akt expression was further noted in specimens serially obtained from individuals with time‐course disease progression. Taken together, these results suggest that aberrant activation of PI3K‐Akt pathway may contribute to increased cell invasiveness and facilitate prostate cancer progression. © 2007 Wiley‐Liss, Inc.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Li, J., Yen, C., Liaw, D., Podsypanina, K., Bose, S., Wang, S. I., Puc, J., Miliaresis, C., Rodgers, L., McCombie, R., et al. (1997) · Science · doi:10.1126/science.275.5308.1943 · Cited by 4,785
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
PI3K/Akt signalling pathway and cancer
Vara, J. Á. F., Casado, E., de Castro, J., Cejas, P., Belda-Iniesta, C., & González-Barón, M. (2004) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2003.07.007 · Cited by 2,443
The protein kinase B/Akt signalling pathway in human malignancy
Nicholson, K. M., & Anderson, N. G. (2002) · Cellular Signalling · doi:10.1016/s0898-6568(01)00271-6 · Cited by 1,639
Chang, F., Lee, J. T., Navolanic, P. M., Steelman, L. S., Shelton, J. G., Blalock, W. L., Franklin, R. A., & McCubrey, J. A. (2003) · Leukemia · doi:10.1038/sj.leu.2402824 · Cited by 1,176
Wang, S., Gao, J., Lei, Q., Rozengurt, N., Pritchard, C., Jiao, J., Thomas, G. V., Li, G., Roy-Burman, P., Nelson, P. S., et al. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00215-0 · Cited by 1,109
Gottlob, K., Majewski, N., Kennedy, S., Kandel, E., Robey, R. B., & Hay, N. (2001) · Genes & Development · doi:10.1101/gad.889901 · Cited by 961
Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems
Podsypanina, K., Ellenson, L. H., Nemes, A., Gu, J., Tamura, M., Yamada, K. M., Cordon-Cardo, C., Catoretti, G., Fisher, P. E., & Parsons, R. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.4.1563 · Cited by 946
AKT plays a central role in tumorigenesis
Testa, J. R., & Bellacosa, A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.211430998 · Cited by 944
Molecular alterations of the AKT 2 oncogene in ovarian and breast carcinomas
Bellacosa, A., De Feo, D., Godwin, A. K., Bell, D. W., Cheng, J. Q., Altomare, D. A., Wan, M., Dubeau, L., Scambia, G., Masciullo, V., et al. (1995) · International Journal of Cancer · doi:10.1002/ijc.2910640412 · Cited by 837
Staal, S. P. (1987) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.84.14.5034 · Cited by 767
Differentiation Stage-Specific Inhibition of the Raf-MEK-ERK Pathway by Akt
Rommel, C., Clarke, B. A., Zimmermann, S., Nuñez, L., Rossman, R., Reid, K., Moelling, K., Yancopoulos, G. D., & Glass, D. J. (1999) · Science · doi:10.1126/science.286.5445.1738 · Cited by 758
McMenamin, M. E., Soung, P., Perera, S., Kaplan, I. D., Loda, M. F., & Sellers, W. R. (1999) · PubMed · Cited by 640
Whang, Y. E., Wu, X., Suzuki, H., Reiter, R. E., Tran, C., Vessella, R. L., Said, J. W., Isaacs, W. B., & Sawyers, C. L. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.9.5246 · Cited by 639
Akt Enhances Mdm2-mediated Ubiquitination and Degradation of p53
Ogawara, Y., Kishishita, S., Obata, T., Isazawa, Y., Suzuki, T., Tanaka, K., Masuyama, N., & Gotoh, Y. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109745200 · Cited by 617 · cited 1×
“Akt has been shown to prolong cell survival by delaying p53-dependent apoptosis through MDM2 phosphorylation.(19) Akt has also been shown to inhibit the Raf-MEK-ERK pathway through phosphorylation of Raf-1 and to overcome constitutively activated MAPK-induced cell cycle arrest.”
BackgroundActivation of the PI3K/Akt pathway and chemotherapeutic resistance
West, K. A., Sianna Castillo, S., & Dennis, P. A. (2002) · Drug Resistance Updates · doi:10.1016/s1368-7646(02)00120-6 · Cited by 585
(2001) · PubMed · Cited by 557
Jiang, B.-H., Zheng, J. Z., Aoki, M., & Vogt, P. K. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.040560897 · Cited by 528
(1997) · PubMed · Cited by 512
Muise-Helmericks, R. C., Grimes, H. L., Bellacosa, A., Malstrom, S. E., Tsichlis, P. N., & Rosen, N. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.45.29864 · Cited by 511
PTEN/MMAC1 mutations in endometrial cancers.
Risinger, J. I., Hayes, A. K., Berchuck, A., & Barrett, J. C. (1997) · PubMed · Cited by 506
Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice
Shioi, T., McMullen, J. R., Kang, P. M., Douglas, P. S., Obata, T., Franke, T. F., Cantley, L. C., & Izumo, S. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2799-2809.2002 · Cited by 506
Disruption of the MMAC1/PTEN gene by deletion or mutation is a frequent event in malignant melanoma.
Guldberg, P., Straten, P. T., Birck, A., Ahrenkiel, V., Kirkin, A. F., & Zeuthen, J. (1997) · PubMed · Cited by 480
Nakatani, K., Thompson, D. A., Barthel, A., Sakaue, H., Liu, W., Weigel, R. J., & Roth, R. A. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.31.21528 · Cited by 475
PIK3CA as an oncogene in cervical cancer
Ma, Y.-Y., Wei, S.-J., Lin, Y.-C., Lung, J.-C., Chang, T.-C., Whang-Peng, J., Liu, J. M., Yang, D.-M., Yang, W. K., & Shen, C.-Y. (2000) · Oncogene · doi:10.1038/sj.onc.1203597 · Cited by 434
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
Vlietstra, R. J., van Alewijk, D. C., Hermans, K., van Steenbrugge, G. J., & Trapman, J. (1998) · PubMed · Cited by 381
Graff, J. R., Konicek, B. W., McNulty, A. M., Wang, Z., Houck, K., Allen, S., Paul, J. D., Hbaiu, A., Goode, R. G., Sandusky, G. E., et al. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m003145200 · Cited by 378
Kreisberg, J. I., Malik, S. N., Prihoda, T. J., Bedolla, R. G., Troyer, D. A., Kreisberg, S., & Ghosh, P. M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0272 · Cited by 324
Immunohistochemical demonstration of phospho-Akt in high Gleason grade prostate cancer.
Malik, S. N., Brattain, M. G., Ghosh, P., Troyer, D. A., Prihoda, T. J., Bedolla, R. G., & Kreisberg, J. I. (2002) · PubMed · Cited by 321
Martin, G. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00216-2 · Cited by 281
Davies, M. A., Koul, D., Dhesi, H., Berman, R. S., McDonnell, T. J., McConkey, D. J., Yung, W. K. A., & Steck, P. A. (1999) · PubMed · Cited by 280
Inhibitors of mTOR reverse doxorubicin resistance conferred by PTEN status in prostate cancer cells.
Grünwald, V., deGraffenried, L. A., Russel, D., Friedrichs, W. E., Ray, R. B., & Hidalgo, M. M. (2002) · PubMed · Cited by 279
Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer
Gao, N., Zhang, Z., Jiang, B.-H., & Shi, X. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2003.09.132 · Cited by 275
Tu, Y., Gardner, A. M., & Lichtenstein, A. K. (2000) · PubMed · Cited by 235
Gupta, S., Hastak, K., Afaq, F., Ahmad, N., & Mukhtar, H. (2004) · Oncogene · doi:10.1038/sj.onc.1207353 · Cited by 218
Self-citationAyala, G., Thompson, T., Yang, G., Frolov, A., Li, R., Scardino, P., Ohori, M., Wheeler, T., & Harper, W. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0477 · Cited by 207
Paez, J., & Sellers, W. R. (2006) · Cancer Treatment and Research · doi:10.1007/0-306-48158-8_6 · Cited by 180
PI3K/PTEN/AKT pathway. A critical mediator of oncogenic signaling.
Paez, J., & Sellers, W. R. (2003) · PubMed · Cited by 173
Chesire, D. R., Ewing, C. M., Gage, W. R., & Isaacs, W. B. (2002) · Oncogene · doi:10.1038/sj.onc.1205352 · Cited by 161
Signaling Pathways Responsible for Cancer Cell Invasion as Targets for Cancer Therapy
Slíva, D. (2004) · Current Cancer Drug Targets · doi:10.2174/1568009043332961 · Cited by 144
Phenotypic and genotypic characterization of commonly used human prostatic cell lines
Mitchell, S., Abel, P. D., Ware, M., Stamp, G., & Lalani, E. (2000) · British Journal of Urology · doi:10.1046/j.1464-410x.2000.00606.x · Cited by 137
Mechanisms of tumour invasion and metastasis: emerging targets for therapy
Thompson, E. W., & Price, J. T. (2002) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.6.2.217 · Cited by 116
Tanaka, M., Koul, D., Davies, M. A., Liebert, M., Steck, P. A., & Grossman, H. B. (2000) · Oncogene · doi:10.1038/sj.onc.1203918 · Cited by 103
Davies, M. A., Kim, S. J., Parikh, N. U., et al. (2002) · PubMed · Cited by 96
Wu, C., & Huang, J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m608487200 · Cited by 91
Zhang, L., Yang, N., Katsaros, D., Huang, W., Park, J.-W., Fracchioli, S., Vezzani, C., de la Longrais, I. A. R., Yao, W., Rubin, S. C., et al. (2003) · PubMed · Cited by 69
Conditional Akt activation promotes androgen-independent progression of prostate cancer
Li, B., Sun, A., Youn, H., Hong, Y., Terranova, P. F., Thrasher, J. B., Xu, P., & Spencer, D. M. (2006) · Carcinogenesis · doi:10.1093/carcin/bgl193 · Cited by 51
Cited by
Chapter 2 PI3K/PTEN Signaling in Angiogenesis and Tumorigenesis
(2009) · Advances in Cancer Research · doi:10.1016/s0065-230x(09)02002-8 · Cited by 620
The PI3K-AKT-mTOR Pathway and Prostate Cancer: At the Crossroads of AR, MAPK, and WNT Signaling
Shorning, B. Y., Dass, M. S., Smalley, M. J., & Pearson, H. B. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124507 · Cited by 616
Dubrovska, A., Kim, S., Salamone, R. J., Walker, J. R., Maira, S.-M., García-Echeverría, C., Schultz, P. G., & Reddy, V. A. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810956106 · Cited by 564
Miao, H., Li, D.-Q., Mukherjee, A., Guo, H., Petty, A., Cutter, J., Basilion, J. P., Sedor, J., Wu, J., Danielpour, D., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.04.009 · Cited by 533
Ulgen, E., Ozisik, O., & Sezerman, O. U. (2019) · Frontiers in Genetics · doi:10.3389/fgene.2019.00858 · Cited by 469
Metadata
- Authors
- Shukla, S., MacLennan, G. T., Hartman, D. J., Fu, P., Resnick, M. I., & Gupta, S.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2007-06-05
- Volume
- 121
- Issue
- 7
- Pages
- 1424-1432
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W2044505245
- Cited by
- 316
- References
- 49
- FWCI
- 5.75
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.